KEPUSTAKAAN

1. Sigarlaki,H.J.O,metodologi Medika,Jakarta,2009. 2. Sigarlaki, H.J.O, Epidemiologi, Infomedika, Jakarta, 2009 3. Fauci AS, Lane HC. Human immunodeficiency syndrome (HIV): AIDS and related disorder. In : Braunwald E, Fauci AS, Kasoer DL, et al (Eds). Harrison's Principles of Internal Medicine. 15th ed. New York: McGrawHill; 2001; p.1852-908. 4. CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. August 2001; p. 1-115. 5. Djoerban Z. Penatalaksanaan AIDS. Dalam : Setiati S, Sudoyo AW, Alwi I, dkk (Eds). Pertemuan Ilmiah Tahunan Ilmu Penyakit Dalam 2000. Jakarta : Pusat Informasi dan Penerbitan FKUI; 2001; hal. 1-8. 6. Nes. Upaya turunkan laju infeksi HIV. Kompas 2001 Nov. 16; hal 10 (Col. l). 7. Chippindale S, French L. HIV counselling and the psychosocial management of patients with HIV or AIDS. Br Med J 2001; 322:1533-5. 8. Mindel A, Tenant M. Natural history and management of early HIV Infection. Br Med J 2001; 322:1290-3. 9. Grant AD, Delock KM. HIV Infection and AIDS in the developing world. Br Med J 2001; 322 :1475-8. 10. Benyamini E, Coico R, Sunshine G. Aquired immunodeficiency syndrome. In: Benyamini E, Jeffrey DJ (Eds). Immunology A Short Course 4th ed. New York : Wiley-Liss; 2000. pp. 361-8. 11. Pillay D. Analysis of prevalence of HIV-1 drug resistance in primary infection. Br Med J 2001; 322 :1087-8. 12. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitors therapy and outcomes inpatients with HIV infection. Ann Intern Med 2000;133 : 21-30. 13. Gilbert DN, Moellering RC, Sande MA. The Stanford Guide to Penelitian kedokteran dan kesehatan,edisi II,Info

Antimicrobial Therapy 31th ed. New York : Antimicrobial Inc; 2001. 14. 2001 USPHS/IDSA. Guidelines for the prevention of opportunistic infections in person infected with human immunodeficiency syndrome. Jul. 2001. p.1-68. 15. Centre of Desease Control. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitor or non nucleoside reverse transcriptase inhibitors. MMWR 2000; 49 (RR 10). 16. American Thoracic Society.Targeted tuberculosis testing and treating off latent tuberculosis infection.Am J Respir Crit Care Med 2000 ; 217 : 41-7. 17. Heyward WL, MacQueen KM, Jaffe HW. Obstacles and progress forward development of a preventive HIV vaccine. Intern Assoc Phys AIDS Care. 2001. 18. Hueppchen NA, Anderson JR, Fox HE. Human immnunodeficiency virus infection. In : Cohen WR (Ed). Complications of Pregnancy 5th ed. Philadelphia: Lippicott Williams and Wilkins ; 2000. pp. 677-91. 19. Mofenson LM, Mantyre JA. Advanced and research directions in the prevention of mother-to-child HIV-1 transmission. Lancet 2000 ; 355 : 2237-44.
20. Newel ML, Peckham C. Vertica transmission of HIV in Europe. In :

Jeffries DJ, Hudson CN (Eds). Viral Infections in Obstetrics and Gynaecology 1st ed. London: Arnold ; 1999. pp. 135-48. 21. CDC. Public Health Services task for recommendations for use of andretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the us. MMWR 2001 ; 50 (RR.11). 22. Ditrame ANRS 049 Study Group. 15-month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children. Lancet 1999; 354 : 2050-7. 23. Guay LA, Musoka P, Fleeting T, et. al. Intrapartum and neonatal single-dose nevirapine compared,with zidovudine for prevention of

mother-to-child transmission of HIV- I in Kampala, Uganda : hivnet 012 randomised trial. Lancet 1999; 354: 795-802. 24. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote dIvoire : a randomised trial. Lancet1999;353:781-5. 25. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudin to reduce vertical transmission of HIV in breastfed children in Cote dIvoire and Burkina Faso : a double-blind placebo-controlled multi-centre trial. Lancet 1999; 353:786-92. 26. Shaffer N, Chuachoowong R, Mock PA, et al. Short-course zidovudine, for perinatal HIV-1 transmission in Bangkok, Thailand : a randomised controlled trial. Lancet 1999; 353 : 773-80. 27. Lambert JS, Mofenson LM, Fletcher CV, et al. Safety and pharmacokinetics of hyperimmune anti HIV immunoglobulin administered to HIV-infected pregnant women of and their newborns. Lancet 1998; 353:1477-82. 28. The European Mode of Delivery Collaboration. Elective caesarean section versus vaginal delivery in preventiop of vertical HIV-1 transmission : a randomised clinical trial. Lancet 1998; 353 : 1035-39. 29. Gcubert TA, Reindell D, Kastner Ralph, et A1. Complications after caesarean section in HIV-1 infected women not taking antiretroviral treatment. Lancet 1999; 353 :1612-4. 30. Newell ML, Lin HH, Kao JH, et al. Caesarean section and risk of vertical transmission of HIV-1 infection. Lancet 1994; 353 : 1464-7. 31. Wise J. Breast feeding safer than mixed feeding for babies of HIV mothers. Br Med J 2001; 322 : 511-3. 32. Coutsoudis A, Pillay K, Spooner E, Kuhn S. Influence of infant-feeding pattern on early mother-to-child transmission of HIV-1 in Durban, South Africa : a prospective cohort study Lancet 1999; 354 : 471-6. 33. Mofenson LM, Lambert JS, Steiehm ER, et al. Risk factors for perinatal

transmission of human immnunodeficiency virus type 1. N Engl J Med 1999; 322 : 385-93. 34. US Departemen of Health and Human Services. Guidelines for the management of occupational exposure to HBV, HCV and HIV